{
  "kind": "treatment",
  "slug": "escitalopram-lexapro",
  "type": "antidepressant",
  "name": "Escitalopram (Lexapro)",
  "summary": "An SSRI commonly used for depression and anxiety disorders.",
  "description": "Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used primarily for major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is the S-enantiomer of citalopram and is generally well tolerated.",
  "category": "medications/antidepressants",
  "tags": [
    "ssri",
    "anxiety",
    "depression"
  ],
  "metadata": {
    "drug_classes": [
      "SSRI",
      "Antidepressant"
    ],
    "therapeutic_categories": [
      "Depression",
      "Anxiety",
      "Mood Disorders"
    ],
    "mechanism_categories": [
      "SSRI"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Lexapro",
      "Cipralex"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary Care",
      "Internal Medicine"
    ],
    "fda_approval_year": 2002
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression",
      "Anxiety"
    ],
    "off_label_uses": [
      "Social Anxiety Disorder",
      "Panic Disorder",
      "OCD"
    ],
    "contraindications": [
      "MAOI use",
      "Known hypersensitivity"
    ],
    "monitoring_required": [
      "Suicidal ideation",
      "Sodium levels",
      "QT interval"
    ],
    "efficacy_rating": {
      "depression": 4,
      "anxiety": 4,
      "overall_tolerability": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "escitalopram",
      "lexapro",
      "ssri",
      "depression",
      "anxiety",
      "antidepressant"
    ],
    "synonyms": [
      "S-citalopram",
      "escitalopram oxalate"
    ],
    "common_misspellings": [
      "lexapro",
      "escitalpram",
      "lexepro"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major Depressive Disorder (MDD)",
        "Generalized Anxiety Disorder (GAD)",
        "Social Anxiety Disorder (off-label)",
        "Panic Disorder (off-label)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Selectively inhibits the serotonin transporter (SERT), increasing synaptic serotonin."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "10 mg once daily",
        "titrate": "Increase by 5–10 mg every 1–2 weeks as tolerated",
        "usual_range": "10–20 mg/day",
        "max": "20 mg/day"
      },
      "geriatric": "Start 5 mg daily; usual 5–10 mg/day",
      "hepatic_impairment": "Max 10 mg/day",
      "renal_impairment": "No adjustment in mild/moderate; use caution in severe"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 5 mg, 10 mg, 20 mg",
        "Oral solution: 1 mg/mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Improvement typically begins within 1–2 weeks for anxiety and 2–4 weeks for mood; full response may take 6–8 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "headache",
        "insomnia or somnolence",
        "dry mouth",
        "sweating",
        "sexual dysfunction"
      ],
      "less_common": [
        "fatigue",
        "diarrhea/constipation",
        "dizziness",
        "weight change"
      ],
      "serious": [
        "hyponatremia/SIADH",
        "QT prolongation (dose/CYP2C19-related)",
        "serotonin syndrome",
        "angle-closure glaucoma"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults.",
      "other": [
        "Serotonin syndrome with other serotonergic agents",
        "QT prolongation risk at higher doses or with CYP2C19 inhibition/poor metabolizers"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Serotonin syndrome",
          "action": "Contraindicated; 14-day washout"
        },
        {
          "with": "Linezolid/Methylene blue",
          "risk": "Serotonin syndrome",
          "action": "Avoid or monitor closely"
        },
        {
          "with": "Other SSRIs/SNRIs, triptans, tramadol, St. John's wort",
          "risk": "Serotonin syndrome",
          "action": "Use caution"
        },
        {
          "with": "CYP2C19 inhibitors (e.g., omeprazole)",
          "risk": "↑ escitalopram levels",
          "action": "Consider max 10 mg/day"
        },
        {
          "with": "Drugs that prolong QT (e.g., certain antipsychotics)",
          "risk": "Additive QT prolongation",
          "action": "Avoid or monitor ECG if risk factors"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Mood/suicidality (especially at initiation and dose changes)",
        "Sodium in at-risk patients (elderly, diuretics)",
        "ECG if high dose, cardiac risk, or interacting drugs",
        "Sleep, weight, sexual side effects, adherence"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use if benefits outweigh risks; possible neonatal adaptation syndrome if used late in pregnancy.",
      "lactation": "Generally compatible; monitor infant for irritability or poor feeding.",
      "pediatrics": "Black box warning applies; dosing individualized.",
      "geriatrics": "Lower starting dose (5 mg) often appropriate."
    },
    {
      "type": "tapering",
      "text": "To discontinue, reduce by 5–10 mg every 1–2 weeks; taper more slowly if withdrawal symptoms occur."
    },
    {
      "type": "clinical_notes",
      "items": [
        "If partial response at 4–6 weeks, consider dose increase to 20 mg/day if tolerated.",
        "For CYP2C19 poor metabolizers or strong inhibitors, avoid >10 mg/day.",
        "Switching from another SSRI usually allows a direct switch; monitor for interactions."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Clinical guidelines summary",
          "url": "https://www.nice.org.uk/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Escitalopram (Lexapro): Dosing, Side Effects, Interactions",
    "description": "Evidence-based overview of escitalopram including dosing, adverse effects, interactions, and monitoring."
  }
}
